Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

The "In" Crowd

Related Content

PTAB Institutes Sarepta’s IPR

Antitrust and Competition Life Sciences Quarterly Update Q2 2024

Update on Recent International Biosimilar Approvals

Regeneron Files BPCIA Complaint Against Sandoz Regarding Aflibercept Biosimilar

FDA Approves Moderna’s and Pfizer/BioNTech’s Updated COVID-19 Vaccines

FTC Comment on FDA Draft Guidance on Interchangeability

Del. Judge Connolly Says Preambles Are Limiting, Cites Alice in Wonderland, and Invites the Federal Circuit to Weigh In

EMA Accepts Marketing Authorization Application for Alvotech’s AVT06 (aflibercept)

Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards

Goodwin Advises Arsenal Biosciences on $325 million Series C Funding Round

Goodwin Advises Collegium Pharmaceutical with Pharmakon Financing for Acquisition of Ironshore Therapeutics

Goodwin Advises eGenesis on $191 million Series D Funding Round

Hepta Medical Raises €5.7 Million in Series A Financing

Haventure Participates in the Fundraising and Creation of Kyniska Robotics

Deal Watch: Taking the Lead in PE Activity, Goodwin Top First Half League Tables (The American Lawyer)

Goodwin is Top Law Firm for M&A and Private Equity

Life Sciences